Stock·NYSE·Healthcare
Veeva Systems Inc. (VEEV)
- Market cap
- $51.52B
- P/E
- 52.16
- Dividend yield
- None
- Street target
- $300.00median of 29 analysts
- 52-week range
- $148.05 $325.99
VEEV stock forecast today
Where VEEV stands today, and what CleaRank Financial AI makes of it.
VEEV at a glance
Veeva Systems Inc. (VEEV): Buy, 74/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($278.42 and $207.56).
- Earnings VEEV beat estimates in 7 of the 7 reports in our data, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $23.6M and made no open-market purchases over the last 18 months.
- Valuation P/E of 52.2 against 31.9 for the Healthcare sector: a premium to peers (+64%).
Figures as of October 26, 2026.
CleaRank Financial AI
CleaRank rates Veeva Systems Inc. (VEEV) Buy, with a model score of 74/100.
The trend lifts the score most: the price is 53.30% above its 200-day average and 14.28% above its 50-day average, and the 50-day average is 34.14% above the 200-day. Valuation holds it back most: the P/E of 52.16 is 63.5% above the sector median (a premium to peers) and the P/S of 15.12 is 344.7% above the sector median. The 50-day average stands at $278.42 and the 200-day at $207.56. Over the past year the price rose 8.59%.
Only on CleaRank
Figures we compute ourselves from VEEV's own price, earnings and insider-filing history. Tap one to see it in context.
VEEV stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $318.18 is 14.3% above the 50-day simple moving average of $278.42.Price above its 200-day average ›
The price is 53.3% above the 200-day simple moving average of $207.56.50-day average above the 200-day ›
The 50-day average ($278.42) is 34.1% above the 200-day average ($207.56), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 96% of its 52-week range, between $148.05 and $325.99.
VEEV share price
Pick a period: each tab shows how far VEEV has moved over it, to the last close.
Today's trading
Where VEEV sits inside today's range and its 52-week range.
VEEV fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/4P/E below the sector median ›
The trailing P/E of 52.16 is 63.5% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 14.90 is 338.2% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $1.0B on revenue of $3.5B, a net margin of 29.3%.Beat estimates in most recent reports ›
VEEV beat the EPS estimate in 7 of the 7 reports in our data.
Key statistics
The headline figures for VEEV.
As of October 26, 2026, VEEV trades at $318.18, with a market value of $51.52B and a P/E ratio of 52.16.
What the numbers say
CleaRank Financial AI's reading of VEEV's valuation, growth and risks.
Veeva Systems Inc. (VEEV) trades at 52.96 times earnings, compared with a Healthcare median of 31.9. That leaves the P/E 66.0% above the median, so the P/E is a premium to peers. On sales, VEEV is priced at 15.12 times, 344.7% above the sector median of 3.4. Its market capitalisation stands at $51.5B, and trailing earnings come to $6.10 a share.
With revenue growth of 17.60%, VEEV is 9.5 percentage points faster than the sector median of 8.1%. The business converts sales into profit at a net margin of 29.35% and an operating margin of 29.64%. It reports a return on equity of 14.43%, above the sector median of 7.3%. The balance sheet rounds out the picture, with debt-to-equity of 0.02.
The company reported $2.35 per share against an estimate of $2.22 for the August 26, 2026 report, beating the estimate by 5.86%. In the first session after the report, the share price climbed 15.20%.
VEEV has beaten the EPS estimate in all 7 reports in our data, though the stock still fell in the first session after 3 of those 7 beats. Analysts' average EPS estimate for this fiscal year is $9.24, which would be growth of 14.0%, and $10.25 for next year (growth of 11.0%).
With a P/E of 52.16, 63.5% above the sector median, VEEV is at a premium to peers, which means weaker results would be judged against a higher bar. A typical day moves the price by 1.87%, measured as the 30-day standard deviation of daily returns, and the beta against the S&P 500 is 0.93.
VEEV against the Healthcare sector
How VEEV compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: VEEV trades at a significant premium to sector peers (+64%), suggesting market expectations for superior growth or market position.
Return vs XLV: Since May 14, 2025, VEEV has gained 32.4% against a gain of 39.2% for XLV.
Performance against XLV
VEEV and the Healthcare sector fund over the same days.
Revenue and earnings
How much VEEV sells, and how much of it becomes profit.
Revenue growth: Revenue grew 16.3% in FY2026 to $3.2B, from $2.7B a year earlier.
Profit margin: The net margin was 28.4% in FY2026, up from 26.0% the year before.
Profitable: VEEV earned $909M in FY2026.
Earnings reality check
Did VEEV beat what analysts expected, and how did the stock react?
Earnings record: VEEV beat the analyst estimate in 7 of the 7 reports in our data.
Market reaction: The stock fell in the first session after 3 of those 7 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 26, 2026after close | $2.22 | $2.35 | +5.86% | +15.20% | +14.62% |
| Jun 3, 2026after close | $2.14 | $2.24 | +4.67% | -0.07% | -8.37% |
| Nov 20, 2025after close | $1.95 | $2.04 | +4.62% | -9.77% | -11.17% |
| Aug 27, 2025after close | $1.90 | $1.99 | +4.74% | -7.24% | -8.01% |
| May 28, 2025after close | $1.74 | $1.97 | +13.22% | +19.00% | +20.93% |
| Mar 5, 2025after close | $1.58 | $1.74 | +10.13% | +7.37% | +6.15% |
| Dec 5, 2024after close | $1.58 | $1.75 | +10.76% | +8.11% | +0.35% |
As of October 26, 2026, VEEV has beaten the analyst EPS estimate in 7 of the 7 reports in our data and fell in the first trading session after 3 of those beats; its latest report, on August 26, 2026, came in 5.86% above the estimate and the stock moved +15.20% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
VEEV AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 70.0, in overbought territory.RSI above 50 ›
An RSI of 70.0 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of VEEV
The score, the reasoning behind it, and what could move the price next.
VEEV's trend points up. The price of $318.18 sits 53.30% above its 200-day average of $207.56 and 14.28% above its 50-day average of $278.42. Near the top of its 52-week range, the price is 2.40% below the high of $325.99 and 114.91% above the low of $148.05. The 50-day average is 34.14% above the 200-day, a configuration that backs up the move instead of working against it.
The 14-day RSI of 70.0 is in overbought territory, and the MACD line is positive. The recent returns are all positive: the price rose 63.62% over the past three months, rose 98.30% over the past six months and rose 8.59% over the past year. Volume in the last session ran 32.6% below its average, on a day the price fell 1.50%.
Earnings beat ›
The August 26, 2026 report beat the EPS estimate by 5.86%, and the share price rose 15.20% in the first session after it.
Source: Earnings report, August 26, 2026Rating reaffirmed ›
Barclays kept its Overweight rating on October 19, 2026.
Source: Analyst action, Barclays, October 19, 2026
- Two levels matter most right now: the 52-week high of $325.99 above the price, and the 20-day EMA at $302.37 below it.
- A 14-day RSI of 70.0 is in the overbought zone, and the MACD line is positive. Readings above 70 or below 30 signal stretched momentum.
- The share price rose 15.20% in the first session after the August 26, 2026 report. VEEV has beaten estimates in 7 of the 7 reports in our data.
VEEV's uptrend depends on the price holding above its 50-day average of $278.42 and its 200-day average of $207.56. A close below the 50-day average would be the first sign that the trend is weakening. If the price pulls back, the first level it would reach is the 20-day EMA at $302.37.
Overhead, the 52-week high of $325.99 is the next level VEEV would meet. With the RSI past the overbought line, a pause in momentum would not be surprising, even though the uptrend would remain intact.
Technical indicators
Momentum and trend for VEEV, from its daily closes.
As of October 26, 2026, with VEEV at $318.18, its 14-day RSI is 70.0 (overbought territory), its 50-day simple moving average is $278.42 and its 200-day is $207.56.
Calculated by CleaRank on daily closes as of October 26, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What VEEV moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 26, 2026, VEEV's 1-year correlation of daily returns is +0.27 with S&P 500 (SPY), +0.22 with Nasdaq 100 (QQQ), +0.16 with Bitcoin (BTC) and -0.01 with gold (XAU).
VEEV price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
20 of 29 analysts rate it a buy or strong buy, 8 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $300.00 is 5.7% below the price.More buy ratings than three months ago ›
20 of 29 rate it a buy now, against 22 of 30 three months ago.
VEEV Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 19, 2026 | Barclays | Maintains | Overweight |
| Aug 28, 2026 | Citigroup | Maintains | Neutral |
| Aug 27, 2026 | Mizuho | Maintains | Outperform |
| Aug 27, 2026 | BMO Capital | Maintains | Market Perform |
| Aug 27, 2026 | Baird | Maintains | Outperform |
| Aug 27, 2026 | Canaccord Genuity | Maintains | Hold |
As of October 26, 2026, 29 Wall Street analysts cover VEEV: 20 rate it a buy or strong buy, 8 a hold and 1 a sell or strong sell. Their 12-month price targets range from $180.00 to $360.00. The median VEEV price target is $300.00, 5.7% below the price of $318.18.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
VEEV trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
VEEV trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from VEEV's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much VEEV tends to move, against the market and on its own.
VEEV price history and drawdowns
VEEV's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move under 2% ›
The price has moved 1.87% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 55.6%, from August 2021 to April 2026; the price is still 6.7% below that peak.Most 1-year holds ended higher ›
70% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $84,286, against $42,015 in the S&P 500 (SPY).
VEEV Drawdowns & Recovery
As of October 26, 2026, VEEV's worst peak-to-trough fall over the last 10 years with dividends reinvested was -55.6% (August 2021 to April 2026); it is still 6.7% below that peak, and 70% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into VEEV in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: VEEV beat the S&P 500 over this period: $84,286 against $42,015.
A $10,000 investment in VEEV in October 2016 would be worth about $84,286 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to VEEV, and which have not.
Strongest month, June: an average of +8.04%, up in 7 of 10 years.
Weakest month, December: an average of -7.08%, up in 2 of 10 years.
This month, October: has averaged -0.55%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, VEEV's strongest calendar month has been June (average +8.04%, up in 7 of 10 years) and its weakest December (average -7.08%, up in 2 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
VEEV stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in VEEV, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in VEEV today could grow to about $15,055 by 2030 in the base case, with a 90th-percentile outcome near $40,665 and a 10th-percentile outcome around $5,573. Projections are statistical simulations, not guarantees.
VEEV Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $479 for VEEV by 2030 in the base case, from $318 today (1.5x over 4 years). The 10th-percentile path ends near $177. These are outcomes of a Monte Carlo simulation run on VEEV's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $214 | $352 | $579 | |
| 2028 | $193 | $390 | $788 | |
| 2029 | $183 | $432 | $1,022 | |
| 2030 | $177 | $479 | $1,294 |
Method: a lognormal simulation of VEEV's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
VEEV insider trading
What the people running the company have bought and sold.
VEEV insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought VEEV shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 26, 2026, VEEV insiders reported 19 open-market sales worth $23.6M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Daniel J Rizzo
Officer
|
Sell | 4.8K | $1.3M |
| Oct 2, 2026 | Jonathan W Faddis
General Counsel
|
Grant | 803 | - |
| Oct 1, 2026 | Jonathan W Faddis
General Counsel
|
Grant | 1.6K | - |
| Oct 1, 2026 | Vipin Kondath
Officer
|
Grant | 168 | - |
| Oct 1, 2026 | Daniel J Rizzo
Officer
|
Grant | 1.7K | - |
| Oct 1, 2026 | Thomas D Schwenger
President
|
Grant | 2.9K | - |
| Oct 1, 2026 | Wagener Brian Van
Chief Financial Officer
|
Grant | 1.6K | - |
| Oct 1, 2026 | Eleni Nitsa A Zuppas
President
|
Grant | 2.2K | - |
| Sep 14, 2026 | Thomas D Schwenger
President
|
Sell | 1.0K | $265.2K |
| Sep 9, 2026 | Priscilla C Hung
Director
|
Sell | 750 | $195.8K |
| Sep 1, 2026 | Timothy S Cabral
Director
|
Grant | 477 | - |
| Sep 1, 2026 | Mark T Carges
Director
|
Grant | 493 | - |
| Sep 1, 2026 | Mary Lynne Hedley
Director
|
Grant | 477 | - |
| Sep 1, 2026 | Priscilla C Hung
Director
|
Grant | 477 | - |
| Sep 1, 2026 | Marshall L Mohr
Director
|
Grant | 525 | - |
| Sep 1, 2026 | Gordon Ritter
Director
|
Grant | 541 | - |
| Sep 1, 2026 | Paul Jai Sekhri
Director
|
Grant | 460 | - |
| Sep 1, 2026 | Matthew J Wallach
Director
|
Grant | 460 | - |
| Aug 27, 2026 | Thomas D Schwenger
President
|
Sell | 10.0K | $2.8M |
| Aug 27, 2026 | Thomas D Schwenger
President
|
Option | 10.0K | $1.5M |
| Aug 13, 2026 | Thomas D Schwenger
President
|
Sell | 36.0K | $9.0M |
| Aug 13, 2026 | Thomas D Schwenger
President
|
Option | 35.0K | $5.4M |
| Jul 16, 2026 | Thomas D Schwenger
President
|
Sell | 5.0K | $1.0M |
| Jul 1, 2026 | Jonathan W Faddis
General Counsel
|
Grant | 1.6K | - |
| Jul 1, 2026 | Vipin Kondath
Officer
|
Grant | 167 | - |
| Jul 1, 2026 | Thomas D Schwenger
President
|
Grant | 2.9K | - |
| Jul 1, 2026 | Wagener Brian Van
Chief Financial Officer
|
Grant | 1.6K | - |
| Jul 1, 2026 | Eleni Nitsa A Zuppas
President
|
Grant | 2.2K | - |
| Jun 1, 2026 | Timothy S Cabral
Director
|
Grant | 262 | - |
| Jun 1, 2026 | Mark T Carges
Director
|
Grant | 271 | - |
| Jun 1, 2026 | Mary Lynne Hedley
Director
|
Grant | 262 | - |
| Jun 1, 2026 | Priscilla C Hung
Director
|
Grant | 262 | - |
| Jun 1, 2026 | Marshall L Mohr
Director
|
Grant | 289 | - |
| Jun 1, 2026 | Gordon Ritter
Director
|
Grant | 298 | - |
| Jun 1, 2026 | Paul Jai Sekhri
Director
|
Grant | 253 | - |
| Jun 1, 2026 | Matthew J Wallach
Director
|
Grant | 253 | - |
| Apr 30, 2026 | Priscilla C Hung
Director
|
Sell | 750 | $116.7K |
| Apr 10, 2026 | Priscilla C Hung
Director
|
Sell | 750 | $115.1K |
| Apr 1, 2026 | Jonathan W Faddis
General Counsel
|
Grant | 8.7K | - |
| Apr 1, 2026 | Vipin Kondath
Officer
|
Grant | 2.6K | - |
| Apr 1, 2026 | Thomas D Schwenger
President
|
Grant | 2.0K | - |
| Apr 1, 2026 | Wagener Brian Van
Chief Financial Officer
|
Grant | 872 | - |
| Apr 1, 2026 | Eleni Nitsa A Zuppas
President
|
Grant | 9.0K | - |
| Mar 5, 2026 | Thomas D Schwenger
President
|
Sell | 1.0K | $200.0K |
| Feb 27, 2026 | Timothy S Cabral
Director
|
Grant | 262 | - |
| Feb 27, 2026 | Mark T Carges
Director
|
Grant | 271 | - |
| Feb 27, 2026 | Mary Lynne Hedley
Director
|
Grant | 262 | - |
| Feb 27, 2026 | Priscilla C Hung
Director
|
Grant | 262 | - |
| Feb 27, 2026 | Marshall L Mohr
Director
|
Grant | 288 | - |
| Feb 27, 2026 | Gordon Ritter
Director
|
Grant | 297 | - |
| Feb 27, 2026 | Paul Jai Sekhri
Director
|
Grant | 253 | - |
| Feb 27, 2026 | Matthew J Wallach
Director
|
Grant | 253 | - |
| Jan 13, 2026 | Thomas D Schwenger
President
|
Sell | 1.0K | $231.4K |
| Dec 31, 2025 | Jonathan W Faddis
General Counsel
|
Grant | 1.2K | - |
| Dec 31, 2025 | Vipin Kondath
Officer
|
Grant | 103 | - |
| Dec 31, 2025 | Thomas D Schwenger
President
|
Grant | 2.0K | - |
| Dec 31, 2025 | Wagener Brian Van
Chief Financial Officer
|
Grant | 871 | - |
| Dec 31, 2025 | Eleni Nitsa A Zuppas
President
|
Grant | 1.5K | - |
| Dec 2, 2025 | Paul Jai Sekhri
Director
|
Grant | 2.5K | - |
| Dec 1, 2025 | Timothy S Cabral
Director
|
Grant | 263 | - |
| Dec 1, 2025 | Mark T Carges
Director
|
Grant | 271 | - |
| Dec 1, 2025 | Mary Lynne Hedley
Director
|
Grant | 263 | - |
| Dec 1, 2025 | Priscilla C Hung
Director
|
Grant | 263 | - |
| Dec 1, 2025 | Marshall L Mohr
Director
|
Grant | 289 | - |
| Dec 1, 2025 | Gordon Ritter
Director
|
Grant | 298 | - |
| Dec 1, 2025 | Paul Jai Sekhri
Director
|
Grant | 254 | - |
| Dec 1, 2025 | Matthew J Wallach
Director
|
Grant | 254 | - |
| Oct 8, 2025 | Thomas D Schwenger
President
|
Grant | 980 | - |
| Oct 7, 2025 | Eleni Nitsa A Zuppas
President
|
Sell | 6.0K | $1.8M |
| Oct 7, 2025 | Eleni Nitsa A Zuppas
President
|
Option | 6.0K | $812.9K |
| Oct 6, 2025 | Jonathan W Faddis
General Counsel
|
Sell | 720 | $214.6K |
| Oct 6, 2025 | Jonathan W Faddis
General Counsel
|
Grant | 5.0K | - |
| Oct 2, 2025 | Jonathan W Faddis
General Counsel
|
Sell | 14.6K | $4.4M |
| Oct 2, 2025 | Thomas D Schwenger
President
|
Sell | 3.4K | $1.0M |
| Oct 2, 2025 | Jonathan W Faddis
General Counsel
|
Option | 15.8K | $2.9M |
| Oct 1, 2025 | Kristine Diamond
Officer
|
Grant | 218 | - |
| Oct 1, 2025 | Thomas D Schwenger
President
|
Grant | 2.0K | - |
| Oct 1, 2025 | Wagener Brian Van
Chief Financial Officer
|
Grant | 872 | - |
| Oct 1, 2025 | Eleni Nitsa Zuppas
President
|
Grant | 1.5K | - |
| Aug 29, 2025 | Timothy S Cabral
Director
|
Grant | 262 | - |
| Aug 29, 2025 | Mark T Carges
Director
|
Grant | 271 | - |
| Aug 29, 2025 | Mary Lynne Hedley
Director
|
Grant | 262 | - |
| Aug 29, 2025 | Priscilla C Hung
Director
|
Grant | 262 | - |
| Aug 29, 2025 | Marshall L Mohr
Director
|
Grant | 289 | - |
| Aug 29, 2025 | Gordon Ritter
Director
|
Grant | 298 | - |
| Aug 29, 2025 | Paul Jai Sekhri
Director
|
Grant | 253 | - |
| Aug 29, 2025 | Matthew J Wallach
Director
|
Grant | 253 | - |
| Jul 10, 2025 | Jonathan W Faddis
General Counsel
|
Sell | 720 | $205.6K |
| Jul 7, 2025 | Priscilla C Hung
Director
|
Sell | 343 | $97.3K |
| Jul 1, 2025 | Kristine Diamond
Officer
|
Grant | 218 | - |
| Jul 1, 2025 | Jonathan W Faddis
General Counsel
|
Grant | 1.2K | - |
| Jul 1, 2025 | Thomas D Schwenger
President
|
Grant | 2.0K | - |
| Jul 1, 2025 | Wagener Brian Van
Chief Financial Officer
|
Grant | 872 | - |
| Jul 1, 2025 | Eleni Nitsa Zuppas
President
|
Grant | 1.5K | - |
| Jun 6, 2025 | Timothy S Cabral
Director
|
Sell | 315 | $91.3K |
| May 30, 2025 | Timothy S Cabral
Director
|
Grant | 315 | - |
| May 30, 2025 | Mark T Carges
Director
|
Grant | 357 | - |
| May 30, 2025 | Mary Lynne Hedley
Director
|
Grant | 343 | - |
| May 30, 2025 | Priscilla C Hung
Director
|
Grant | 343 | - |
| May 30, 2025 | Nimrata Hunt
Director
|
Grant | 343 | - |
| May 30, 2025 | Marshall L Mohr
Director
|
Grant | 385 | - |
| May 30, 2025 | Gordon Ritter
Director
|
Grant | 399 | - |
| May 30, 2025 | Paul Jai Sekhri
Director
|
Grant | 329 | - |
| May 30, 2025 | Matthew J Wallach
Director
|
Grant | 329 | - |
| May 29, 2025 | Thomas D Schwenger
President
|
Sell | 1.2K | $308.3K |
| May 2, 2025 | Jonathan W Faddis
General Counsel
|
Sell | 833 | $197.2K |
Source: TwelveData, from SEC Form 4 filings
VEEV stock forecast: questions people ask
Answered from the figures on this page, as of October 26, 2026.